Exenatide vs Octreotide
Overview
Exenatide is primarily a weight management & metabolic peptide, while Octreotide is used for hormonal.
This page compares Exenatide and Octreotide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Exenatide | Octreotide | |
|---|---|---|
| Category | Weight Management & Metabolic | Hormonal |
| Regulatory status (US) | FDA approved | FDA approved |
| Typical dosage | 5–10 mcg (Byetta) or 2 mg (Bydureon/Bydureon BCise) | 20–30 mg (LAR formulation, IM every 4 weeks); 100–600 mcg/day in divided doses (immediate-release SC) |
| Frequency | Twice daily (Byetta) or once weekly (Bydureon) | Every 4 weeks (LAR); two to four times daily (immediate-release) |
| Reported benefits | Glycemic control (HbA1c reduction 0.8–1.9 percentage points), modest body weight reduction (2–4 kg), low intrinsic hypoglycemia risk, modest systolic blood pressure reduction, cardiovascular non-inferiority established in EXSCEL | Reduction of growth hormone and IGF-1 in acromegaly, suppression of carcinoid flushing and diarrhea, control of VIPoma-associated watery diarrhea, antiproliferative effect on low-grade neuroendocrine tumors, reduction of urinary 5-HIAA biomarkers |
| Reported side effects | Nausea, vomiting, diarrhea, injection site reactions, hypoglycemia (when co-administered with sulfonylureas), rare acute pancreatitis, rare acute kidney injury | Gallstones and biliary sludge, diarrhea, nausea, abdominal discomfort, sinus bradycardia, hyperglycemia, hypoglycemia, hypothyroidism, steatorrhea, injection-site pain |
Key differences
Primary use. Exenatide is categorised under Weight Management & Metabolic, while Octreotide falls under Hormonal. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Exenatide: FDA-approved. Octreotide: FDA-approved.
Dosing. Exenatide is typically dosed at 5–10 mcg (Byetta) or 2 mg (Bydureon/Bydureon BCise) (Twice daily (Byetta) or once weekly (Bydureon)). Octreotide is typically dosed at 20–30 mg (LAR formulation, IM every 4 weeks); 100–600 mcg/day in divided doses (immediate-release SC) (Every 4 weeks (LAR); two to four times daily (immediate-release)).
Can you stack them?
Some protocols combine peptides, but stacking Exenatide and Octreotide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Exenatide and Octreotide?
- Exenatide is primarily a weight management & metabolic peptide, while Octreotide is used for hormonal. Exenatide is FDA-approved for one or more indications, whereas Octreotide is FDA-approved for one or more indications.
- What is Exenatide used for?
- FDA-approved GLP-1 receptor agonist for type 2 diabetes; the first incretin mimetic approved in the US.
- What is Octreotide used for?
- FDA-approved somatostatin analog for acromegaly, carcinoid syndrome, and VIPomas since 1988.
- Can you take Exenatide and Octreotide together?
- Some users combine peptides within a single protocol, but stacking Exenatide and Octreotide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Exenatide or Octreotide FDA-approved?
- Exenatide is FDA-approved for one or more indications. Octreotide is FDA-approved for one or more indications.
Read the full articles
- Exenatide — full monograph: mechanism, research, dosing & references
- Octreotide — full monograph: mechanism, research, dosing & references